Carbon Reduction Plan

Supplier name: Bristol Myers Squibb

Publication date: May 29th, 2025

Commitment to achieving Net Zero

Bristol Myers Squibb is committed to reaching net-zero greenhouse gas (GHG) emissions across our value chain by 2050 and this commitment is supported and adopted by Bristol-Myers Squibb Business Services Limited, Bristol-Myers Squibb Pharmaceuticals Limited, and Celgene Europe Limited (collectively, BMS UK). This goal was approved by the Science Based Target initiative (SBTi) in 2024. The information and data contained in this report relates to Bristol-Myers Squibb Company globally, of which BMS UK are wholly owned subsidiaries. The environmental measures stated herein are able to be applied by BMS UK when performing any relevant contracts.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year:	2022
Additional Details relating the Baseline Emissions Calculations	
BMS follows the GHG Protocol to measure our combined enterprise GHG emissions for our Scope 1, Scope 2 and 10 categories of our Scope 3 and has the data externally verified with limited assurance. We utilize an operational control approach (as defined by the GHG Protocol) in which we report on all owned and leased sites that meet the following criteria: (a) all manufacturing sites, regardless of size; (b) research and development (R&D) sites that are greater than 50,000 square feet; and (c) distribution centers, warehouses and offices that are greater than 100,000 square feet. For entities out of this scope, we follow a similar philosophy, stiving to reduce emissions, energy, waste and water.	
Baseline Year Emissions: 2022	
EMISSIONS	**TOTAL (tCO2e)**
Scope 1	**BMS Enterprise:** 211, 936

Scope 2 (Location Based)	**BMS Enterprise:** 155,100
Scope 3 (Included Sources)	**Indirect GHG from Value Chain (total):** 1,768,500 **Category 1—Purchased Goods & Services:** 1,354,700 **Category 2—Capital Goods:** 19,900 **Category 3—Fuel & Energy-Related Activities:** 71,900 **Category 4—Upstream Transportation & Distribution:** 137,300 **Category 5—Waste Generated in Operations:** 4,400 **Category 6—Business Travel:** 57,200 **Category 7—Employee Commuting:** 58,300 **Category 9 – Downstream transportation & distribution:** 6,700 **Category 12 – End-of-Life Treatment of Sold Products:** 3,200 **Category 15 – Investments**: 54,900 **Biogenic Carbon:** 876
Total Emissions	**BMS Enterprise:** 2,142,307

Current Emission Reporting

Reporting Year Emissions: 2023

Please see our most recent TCFD-aligned Climate Report for additional details. We are providing 2023 emissions data, as 2024 figures are not yet available and currently undergoing limited assurance. We plan on disclosing our 2024 figures on a later date.

The UK country specific results are reported through SECR but have not been externally verified. Our SECR reports are also included in the appendix.

EMISSIONS	**TOTAL (tCO2e)**
Scope 1	**BMS Enterprise:** 208,535
Scope 2 (Location Based)	**BMS Enterprise:** 158,817
Scope 3 (Included Sources)	**Indirect GHG from Value Chain (total):** 1,750,947 **Category 1—Purchased Goods & Services:** 1,353,368 **Category 2—Capital Goods:** 23,745 **Category 3—Fuel & Energy-Related Activities:** 72,108 **Category 4—Upstream Transportation & Distribution:** 131,064 **Category 5—Waste Generated in Operations:** 3,839 **Category 6—Business Travel:** 65,504 **Category 7—Employee Commuting:** 49,734 **Category 9 – Downstream transportation & distribution:** 6,321 **Category 12 – End-of-Life Treatment of Sold Products:** 3,292

	Category 15 – Investments: 41,971 **Biogenic Carbon:** 948
Total Emissions	**BMS Enterprise:** 2,117,929

Emissions reduction targets

BMS has set ambitious goals to reach net-zero greenhouse gas (GHG) emissions across our value chain by 2050, starting from a 2022 baseline. We are on track for a 55% reduction in Scopes 1 and 2 GHG emissions, as well as Scope 3 emissions from fuel and energy-related activities (FERA) by 2033. We are also working closely to engage with 75% of our suppliers by emissions1 in their development of science-based targets by 2028

Carbon Reduction Projects

Completed Carbon Reduction Initiatives

At BMS, we are dedicated to understanding and minimizing our environmental impact as part of our broader commitment to climate action and responsible business practices. Our metrics and targets are essential tools in this endeavor, enabling us to track our progress in reducing our environmental footprint and effectively manage the material climate-related risks and opportunities we face.

In 2024, we strengthened our commitment through our approval of our near-term and long-term goals by the Science-Based Targets initiative (SBTi), which provides a rigorous framework for setting and achieving emissions reduction targets in line with the latest climate science:

BMS has made a commitment to reach net-zero greenhouse gas (GHG) emissions across its value chain by 2050, using 2022 as the baseline year. This ambitious goal underscores our dedication to playing a part in limiting global warming and contributing to a sustainable future. As we move forward, we are committed to refining and expanding our metrics and performance targets when appropriate.

Renewable Energy

Virtual power purchase agreements (VPPAs) are an important part of BMS' strategy to meet our target to achieve 100% of purchased electricity from renewable sources by the end of 2030. In 2022, we executed a 15-year VPPA for 60 megawatts (MW) at the Cattlemen Solar Park in Texas.

The Cattlemen facility came online in 2024, contributing to BMS' 2024 GHG reductions. In late 2023, we signed an additional VPPA for 145 MW in Falls County, Texas. The Blevins Solar & Storage Project is expected to go online in 2026. In combination, these two projects are intended to cover 100% of BMS' North American electricity consumption.

In support of our 2030 renewable electricity goal, we also engaged in a comprehensive review of our European electricity loads, with the purpose of understanding our options for sourcing renewable electricity within these markets. BMS also owns and operates onsite photovoltaic assets across six different facilities in the U.S., the U.K., China and the Netherlands. In aggregate, these onsite installations constitute over 2 MW of generation capacity.

Emissions Reduction

During 2023, BMS implemented more than 70 projects to reduce energy use and greenhouse gas (GHG) emissions across our operations which includes:

- Installation of boiler stack economizers at one BMS site, a waste heat recovery system used to preheat water for various applications.
- Air change rate reductions in lab environments, retrofitting lab fume hoods with automatic sash controls.
- Chiller plant optimization sequences on three major chiller plants.
- Lighting control upgrades and HVAC sequence upgrades

Throughout the year, we also invested in multiple decarbonization studies to understand the potential impact of various projects. This included waste heat recovery programs and the viability of geothermal heat pumps. We recognize the need for continuous improvement and adaptability and will continue to investigate new and emerging technologies to help us achieve our near-term and Net-Zero targets.

With more than 130 facilities in 44 countries, BMS sites include highly regulated and FDA-approved manufacturing plants, specialized R&D locations, and office space designed for employee engagement and collaboration. We design these varied workspaces to support our core mission of developing life-transforming pharmaceuticals—and to minimize environmental impact across multiple dimensions:

- Energy efficiency and energy alternatives to fossil fuels.
- Water savings through facility and process design and conservation.
- Waste reduction through facility design and construction and reuse/recycling.

BMS is an award-winning participant in Energy Star, a joint program of the U.S. Environmental Protection Agency (EPA) and Department of Energy (DOE), which advances performance and innovation for energy efficiency and decarbonization. Our Princeton Pike and Nassau Park facilities in New Jersey, as well as our facility in Tampa, Florida, rate highly on the Energy Star Certified Building scorecard. BMS participates in the U.S. Department of Energy's Better Plants program, which helps us find ways to boost energy efficiency, increase resiliency and reduce our carbon footprint. We have also been accepted into the DOE's Oak Ridge National Laboratory training program. Leadership in Energy and Environmental Design (LEED) Certification, another respected environmental program, rates 16 of our buildings in the U.S., Australia and Ireland as LEED Gold or Silver.

We're enhancing energy efficiency across our operations, with initiatives like heat pump conversion, chiller plant optimization and boiler upgrades, which have yielded significant energy and cost savings. Over $3 million has been allocated for projects to drive demand side reductions and reduce GHG emissions. Our research and development site in Moreton, UK received an A+ Energy Performance Certificate (EPC) rating, making it the fourth highest-rated building to date in the entire England and Wales region. This was achieved through increased insulation, variable refrigerant flow (VRF) air conditioning and 365 photovoltaic panels that generate annual energy of 110 MWh or more.

Bristol-Myers Squibb Pharmaceuticals Limited continues to achieve direct savings in energy and associated carbon emissions through ongoing operational and technological improvements. At its Moreton and Uxbridge sites—where the latter is an office facility co-located with Celgene Europe Limited—a range of initiatives were implemented.

At the Moreton site, these included the installation of a new, updated main electricity AMR meter, implementation of transition space occupancy time controls on all AC units, and a reduction in variable speed drive use in the Material Science Lab. Additional measures included placing Building 1's AHU No.5, which serves office areas, under occupancy time control, upgrading LED lighting in new occupancy areas of Building 4, launching an energy awareness programme for lab staff in Building 3, and deploying the Enerlutec Energy Dashboard across the entire site.

At the Uxbridge site, Bristol-Myers Squibb Pharmaceuticals Limited undertook a range of initiatives as part of its continued efforts to improve energy efficiency and reduce carbon emissions. Key actions included the development of a site-wide energy strategy and the recommissioning of both the LED lighting system and building controls in Building 2. The site also reduced occupied areas on quiet days and secured a renewable electricity contract. Long-term upgrades for the Building 2 plant room are under review, and new landlord meters were installed in Building 3. Several behavioural and operational initiatives were introduced, such as "switch off" campaigns encouraging staff to turn off monitors and docking stations when not in use, staff education on energy usage, and monitoring of MDF/IDF temperatures. Additionally, the site implemented a "print evolution" campaign to reduce printer usage, consolidated occupancy by vacating Building 3 and moving operations into Building 2, and adjusted optimiser settings and main plant startup and shutdown times based on peak office occupancy to further reduce energy consumption.

Supplier Engagement

BMS is proud to be part of several collective efforts taking meaningful action toward sustainability goals. These innovative programs are designed to support the pharmaceutical supply chain, which represents approximately 80% of the industry’s GHG emissions.

- Manufacture 2030 Program: To accelerate environmental impact reduction across our Active Pharmaceutical Ingredients (API) suppliers, BMS cofounded, along with our peer companies, the Manufacture 2030 (M2030) activate program. This initiative recognizes that API production accounts for a significant proportion of the industry’s carbon footprint and that our suppliers are at various stages of their sustainability journey. We seek to address this challenge by collaborating with our suppliers to align with science-based decarbonization targets, drive sustainable procurement, and identify opportunities for operational and resource efficiency. As a participating pharmaceutical company, we also have access to the decarbonization pathway projections of our API suppliers. This increased visibility will aid our own climate risk assessments, allow us to support our suppliers in meeting their climate targets, and strengthen the resiliency of our value chain.
- Energize Initiative: The Energize program is designed to increase access to renewable energy for pharmaceutical suppliers through resources and expertise, as well as the opportunity to participate in power purchase agreements (PPAs). The program is facilitated by Schneider Electric and sponsored by industry leading pharmaceutical companies (including BMS) that have committed to engaging and supporting suppliers on the adoption of renewable energy. In 2023, Energize received industry recognition with the 2023 CPHI Sustainability Award, which has helped propel program adoption and growth. BMS is proud of the participation and engagement its suppliers have shown to date. At the close of 2023, there were approximately 150 suppliers registered, with 100 of these being active users and/or having taken steps in their advancement of renewable energy. Nearly two dozen are considered good candidates for VPPAs
- Converge Program: My Green Lab, the U.N.-aligned certification program described in the Employee Engagement in Sustainability section of this ESG Report, launched a new supplier initiative called Converge at the COP28 U.N. Climate Change Conference. Converge intends to harness the collective power of the pharmaceutical industry to encourage suppliers to reduce the impact of their labs through My Green Lab certification. BMS is a founding sponsor company in the Converge program, which aspires for the pharmaceutical sector to lead the world on supply chain engagement with a thriving value of sustainability across every supplier lab and every scientist.

Additionally, BMS has set an ambitious Scope 3 SBTi goal, committing that 75% of our suppliers by emissions, covering Purchased Goods & Services (PG&S), Capital Goods (CG), and Upstream Transportation & Distribution (UT&D), will have science-based targets (SBTs) by 2028. We recently launched our BMS Supplier Decarbonization Accelerator as a mechanism to support our suppliers with resources and support. The program takes a collaborative approach focused on engagement and education to support suppliers at all levels of climate maturity and provide them with resources to help them on their emissions reduction journey.

Product Sustainability

We also look for ways to consolidate product packaging, to reduce packaging by moving to durable solutions (i.e., reusable and/or recyclable solutions), implement twin-deck vehicles to move high-volume shipments, and identify more effective and efficient shipping routes. Some of our key initiatives in 2023 included:

- The implementation of reusable thermal blankets in place of single-use blankets for keeping our products' temperature secure.
- The exploration of multi-use temperature loggers.
- The implementation of reusable high-performance passive pallet shippers in place of active containers.
- Transitioning to new energy-efficient active containers from legacy containers that were less efficient.

For our temperature-sensitive products, we implemented the use of reusable battery-operated refrigerated pallet-sized containers and passive refrigeration when we have smaller, parcel-sized shipments. We are also exploring alternatives for shipping frozen critical medicines. We aim to expand the use of reusable parcel containers beyond North America, where they are currently utilized. BMS also participates in the Green Suppliers Network and Rx-360, a consortium of major pharmaceutical companies and suppliers that seeks to enhance patient safety by developing a global quality system that helps members ensure product quality and authenticity throughout the pharmaceutical supply chain.

Shipping and Logistics

We work closely with our logistics providers to reduce our environmental impact. In 2023, along with a key supplier, we conducted our first-ever sustainability treasure hunt and identified initiatives to improve our environmental impact. An important initiative was a project to convert from single-use packaging to reusable packaging, which will help reduce our waste-to-landfill rate. The mode of transport that we choose for our products— whether ground, air or ocean—plays an important role in how we operate sustainably. We identify opportunities to transition from air to ocean, and we also reduce the number of shipments per annum, and work with suppliers who can provide more efficient ground transportation via fuel-efficient fleets.

A cross-functional BMS team identified a solution to simulate product shipment and movement, using vibration technology in a laboratory environment to replace real-world test shipments. This innovative approach is estimated to save more than $1 million annually; reduce our transportation emissions footprint; and significantly save time by eliminating the transport, customs, prep and logistics monitoring involved with test shipments.

Transition to electric vehicles in our commercial fleet

We are committed to transforming our commercial fleet to 100% electric vehicles (EVs) by 2040. As a result, we currently manage an on-site EV charging network consisting of 155 EV charging points and more than 500 subscribers across 10 U.S. sites. In 2023, we

introduced plug-in hybrid electric vehicles from Volvo, BMW and Toyota in our U.S. Field Force and developed a home-charging reimbursement policy for drivers

Waste

We strive to minimize waste across our global facilities and operations, and we are proud of the progress we have made toward our goal of zero waste-to-landfill by 2040.

Through the individual and collective efforts of our people and suppliers, we identify and implement measures to reduce, reuse and recycle materials. Additionally, BMS continually assesses our hazardous waste management program for material reuse and waste reduction opportunities in parallel with disposal options. We work with our external waste management partners to identify new waste disposal technologies, and with our internal business teams to decrease the number of hazardous materials needed in our operations.

Water

BMS continuously seek ways to reduce our impact on water withdrawal and to find better mechanisms of water treatment. This includes establishing water balances and mass balances, metering master plans aimed at developing facility-wide water-reduction strategies, improving the treatment of wastewater, and collaborating with internal and external partners to find opportunities for water stewardship and conservation. In the past year, we updated our assessment of locations where BMS operations/facilities occur in water-stressed areas, and we have plans to focus on water stewardship activities on these areas.

BMS redefined our Water Equity Goal by 2040, defining measurable goals and timelines to implement water stewardship across our operations by 2040. We embarked on the first phase of an enhanced water stewardship program, including the identification of associated goals across three focus areas: (1) implement Alliance for Water Stewardship standards at BMS sites operating in stressed watersheds; (2) reduce water footprint in BMS' direct operations through conservation, reduction, reuse and/or other innovations; and (3) increase our understanding of the water footprint of our external supply chain.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard[4] and uses the appropriate Government emission conversion factors for greenhouse gas company reporting[5].

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard[6].

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Supplier:

Signature: Ong, Bee Peng (00384733) Digitally signed by Ong, Bee Peng (00384733) Date: 2025.05.29 14:53:46 +01'00'

Date: May 29th, 2025

[4] https://g hg protocol.o rg/co rpo rate-standard

[5] https ://www.g ov . uk/government/collections/government-conversion-factors-for-co mpany-repo rting

[6] https ://g hg protocol.o rg/stand ards/sco pe-3-stand ard